Keynote-048 found pembrolizumab plus platinum and 5-fluorouracil was effective for all R/M HNSCC patients and pembrolizumab monotherapy was effective for programmed death-ligand 1 (PD-L1)-positive R/M HNSCC patients [6]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.